Skip to content

U-100 unit conversion

Semaglutide calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

16.7U-100 units · 0.167 mL

15 mcg per unit · 1500 mcg/mL

How the calculator works, sources and review dates

Semaglutide math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 3 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-13. source-curated; clinician review pending.

Units chart for listed Semaglutide sizes

U-100 math for listed Semaglutide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
3 mg301510
5 mg502516.7
6 mg603020

What is Semaglutide?

Other names include Wegovy, Ozempic, Rybelsus, S-5, and several milligram research labels. Pills do not share one approval with injections. Research listings sit in a third bucket. DailyMed is the cited label home for the approved product used here.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Product label

Approved product label

People meeting the labeled obesity/overweight and related indication criteria; evidence is product and indication specific.

Reported findings. In a 68-week randomized trial of 1,961 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes, estimated average weight loss was 14.9% with weekly subcutaneous Wegovy assigned to 2.4 mg, versus 2.4% with placebo. Doses increased over 16 weeks; both groups received diet and physical-activity support. These are study results, not dosing advice.

Nonresponse. At least 5% weight loss was reached by 83.5% with Wegovy versus 31.1% with placebo. Some participants did not reach that threshold; group averages do not predict an individual result.

Harms. Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.

Limits. Labeled preparation only; marketed variants do not inherit approval. This intention-to-treat analysis included all randomized participants and estimated missing week-68 weights from participants in the same assigned group. These injection results do not establish outcomes for oral, compounded or research preparations, or food-noise and personal quality-of-life benefits.

Preparation: Wegovy; other approved semaglutide products have different indications. Route: subcutaneous injection

Read original source ↗

Editorial review 2026-10-13. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

approved product. Wegovy; other approved semaglutide products have different indications.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research

product specific. People meeting the labeled obesity/overweight and related indication criteria; evidence is product and indication specific.

Sport

unknown. Not individually verified; consult your sport authority.

How long it lasts, how you store it, listed sizes

168 hours. Approximately one week in the Wegovy label; a pharmacokinetic observation, not a schedule.

The vendor file lists 3 mg, 5 mg, and 6 mg research sizes. Approved-device storage is printed on that carton. This page does not reprint the carton.

Risks and mix-ups already on the record

  • Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
  • Personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity: see the full product label.
  • Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Approved product label · checked 2026-10-09
  2. STEP 1 (PubMed 33567185) · checked 2026-10-09
  3. FDA concerns about unapproved GLP-1 drugs · checked 2026-10-09

Questions people ask

Does this page pick a Wegovy amount?

Labeled amounts live on the product label and with a licensed clinician. The calculator only converts numbers you type.

Why list research vial sizes at all?

People already hold those vials and ask how the U-100 math works. The chart lists a size so the algebra is visible.

How many units is a listed Semaglutide vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.